Side Effect Driven Conversion to Belatacept for Kidney Transplant Recipients in a Clinical Setting
Elizabeth Cohen1 , Richard N Formica2 , and Ramesh K Batra3 *
Journal Title:Journal of Clinical And Experimental Immunology
Maintenance immunosuppression after kidney transplantation is critical to graft and patient survival. However, the optimal immunosuppressive medication may differ for patients based on adverse effects. Here we report one-year outcomes of 73 kidney transplant patients converted from tacrolimus to belatacept because of adverse effects at least 90 days after transplant.